MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
33.00
+0.93
+2.90%
Opening 14:54 12/18 EST
OPEN
32.30
PREV CLOSE
32.07
HIGH
34.78
LOW
32.30
VOLUME
40.76K
TURNOVER
--
52 WEEK HIGH
35.16
52 WEEK LOW
7.65
MARKET CAP
700.20M
P/E (TTM)
-1.4824
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LYEL last week (1208-1212)?
Weekly Report · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Clearwater Analytics, Silver miners, Exxon
Reuters · 12/09 16:00
BUZZ-H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression
Reuters · 12/09 15:18
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 12/09 14:06
Lyell Immunopharma Price Target Raised to $45.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 12/09 11:39
Lyell Immunopharma Raised to Buy From Neutral by HC Wainwright & Co.
Dow Jones · 12/09 11:39
HC Wainwright & Co. Upgrades Lyell Immunopharma to Buy, Raises Price Target to $45
Benzinga · 12/09 11:30
LYELL IMMUNOPHARMA INC <LYEL.O>: H.C. WAINWRIGHT RAISES TO BUY FROM NEUTRAL; RAISES TARGET PRICE TO $45 FROM $20
Reuters · 12/09 11:16
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.